Silymarin's Advantage on Graft Effectiveness

Inclusion Criteria: * First or second kidney transplant recipient * Deceased or living donor kidney transplant * Patients receiving standard immunosuppression regimen: * Tacrolimus or cyclosporine + Mycophenolate mofetil + Corticosteroids * Body Mass Index (BMI) 18-35 kg/m² * Willingness to provide informed consent * Ability to understand and comply with study procedures * Stable medical condition without significant comorbidities Exclusion Criteria: * Multi-organ transplant recipients * Recipients of ABO-incompatible or highly sensitized transplants * Active infectious complications at the time of transplantation: HIV, Active hepatitis B or C, Active cytomegalovirus (CMV) infection * Patients with known liver disease: Cirrhosis, Active hepatitis, ALT or AST \> 2.5 times the upper limit of normal * Significant cardiovascular disease: Recent myocardial infarction (within 6 months), Unstable angina, Severe heart failure (NYHA Class III or IV) * Malignancy within the past 5 years (except successfully treated non-melanoma skin cancer) * Current or recent (within 30 days) participation in another clinical trial * Pregnancy or planned pregnancy during the study period * Known allergy or hypersensitivity to silymarin or milk thistle * Patients taking medications with significant interactions with silymarin: Anticoagulants, Cytochrome P450 enzyme modulators * Psychiatric conditions that may interfere with study compliance * Uncontrolled diabetes mellitus (HbA1c \> 8.5%) * History of non-compliance with medical treatment * Patients with known genetic disorders affecting drug metabolism